This Article Full Text Full Text (PDF) All Versions of this Article: 40/3_suppl_1/S149    most recent STROKEAHA.108.533208v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wechsler, L. R. Search for Related Content PubMed PubMed Citation Articles by Wechsler, L. R. Related Collections Other Stroke Treatment - Medical

(Stroke. 2009;40:S149.)
© 2009 American Heart Association, Inc.

Stem Cell Therapy

Clinical Trials of Stroke Therapy

Which Cells, Which Patients?

From the UPMC Stroke Institute, Department of Neurology, University of Pittsburgh Medical School, Pittsburgh, Pa.

Correspondence to Lawrence R. Wechsler, MD, Director, UPMC Stroke Institute, Professor of Neurology, University of Pittsburgh Medical School, C426 PUH, 200 Lothrop St, Pittsburgh, PA 15217. E-mail wechslerLR@upmc.edu

Key Words: clinical trials • stroke therapy

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Despite recent advances in stroke prevention and acute stroke therapy, few treatments exist for reversal of fixed neurological deficits after stroke. Cellular therapy offers the possibility of improving neurological deficits months or even years after stroke. Animal studies provide evidence that such treatment may be effective. Many questions, however, remain unanswered regarding cellular therapy for stroke. In view of the significant differences between animal models and human stroke, some questions might be best addressed with clinical trials.

	Clinical Trials of Cellular Therapy

 
Completed clinical trials of cellular therapy for stroke are summarized in the Table. Kondziolka et al reported the results of a Phase I study of 12 patients with completed stroke involving the basal ganglia treated with human neuronal cells derived from an immortalized tumor cell line (LBS cells).¹ Either 2 or 6 million cells were implanted stereotactically between 6 months and 6 years after stroke. Patients were followed clinically as well as with MRI and positron emission tomography scans. The same group subsequently performed a Phase II study with randomization of 18 patients to either implantation of 5 or 10 million cells and rehabilitation (14 patients) or rehabilitation alone (4 patients).² Follow-up neurological evaluations were blinded to treatment status. Savitz et al reported the results of transplantation of fetal porcine cells implanted stereotactically in 5 patients with basal ganglia stroke 3 months to 10 years after onset.³ The study was discontinued due to adverse events in 2 patients. In a study by Bang et al, autologous mesenchymal stem cells were given intravenously . . . [Full Text of this Article]